Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Dr. Eng Discusses the BEACON CRC Study in BRAF-Mutated CRC

April 17th 2019

Cathy Eng, MD, professor of gastrointestinal and medical oncology, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the BEACON CRC study in patients with BRAF-mutated colorectal cancer.

Dr. Mahipal on Maintenance Therapy in CRC

April 16th 2019

Amit Mahipal, MBBS, senior associate consultant, Division of Medical Oncology, Department of Oncology, associate professor of oncology, Mayo Clinic, discusses maintenance therapy in colorectal cancer (CRC).

Targeted Treatments Usher in Individualized Care in mCRC

April 15th 2019

Jonathan Mizrahi, MD, discusses recent pivotal data in colorectal cancer and its impact on personalized care in the treatment paradigm.

Dr. Fakih on the Use of Regional Therapy in Colorectal Cancer

April 11th 2019

Marwan Fakih, MD, professor, Department of Medical Oncology and Therapeutics Research, associate director for Clinical Investigations, Comprehensive Cancer Center, medical director, Judy and Bernard Briskin Center for Clinical Research, co-director, Gastrointestinal Cancer Program, and section head, Gastrointestinal Medical Oncology, City of Hope, discusses the use of regional therapy in the treatment of patients with colorectal cancer (CRC).

Dr. Marshall on HER2 Amplification in Colorectal Cancer

April 8th 2019

John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown-Lombardi Comprehensive Cancer Center, discusses HER2 amplification in colorectal cancer (CRC).

Dr. Lee on Tailoring Treatment to Tumor Sidedness in mCRC

April 4th 2019

Michael S. Lee, MD, assistant professor of medicine, Department of Molecular Therapeutics, UNC Lineberger Comprehensive Cancer Center, discusses tailoring treatment to tumor sidedness in patients with metastatic colorectal cancer.

Dr. Salem on the Results of the MyPathway Trial in mCRC

April 3rd 2019

Mohamed E. Salem, MD, a medical oncologist at Levine Cancer Institute, Atrium Health, discusses the results of the MyPathway trial in metastatic colorectal cancer (mCRC).

Refinement of Techniques and the Future of mCRC

March 29th 2019

Improving Responsiveness With Immunotherapy in mCRC

March 29th 2019

Dosing Strategies and Patient Support in mCRC

March 29th 2019

Optimizing Dosing in Patients With mCRC

March 29th 2019

Adjusting the Lines of Therapy Indication in mCRC

March 29th 2019

Puzzling Together the Pieces in mCRC

March 29th 2019

The Influx of Younger Patients With Advanced CRC

March 29th 2019

Sequencing for BRAF+, RAS+, HER2- Left-Sided CRC

March 29th 2019

Multidisciplinary Approach to Resection in mCRC

March 29th 2019

Tissue-Based Testing Versus Liquid Biopsy in mCRC

March 29th 2019

Considering the Basics in Newly Diagnosed mCRC

March 29th 2019

Molecular Markers Gaining Greater Influence in CRC Paradigm

March 27th 2019

Mohamed E. Salem, MD, highlights ongoing research efforts to potentially improve survival in patients with metastatic colorectal cancer.

Testing, Treatment Options Added to NCCN CRC Guidelines

March 25th 2019

A theme of the 2019 NCCN Annual Conference was the expansion of biomarker testing to guide treatment, and a review of brand-new changes for guidelines in colorectal cancer was no different.